Should You Trim Or Add To Your Moderna Position Now?
For questions about this article or underlying research, email help@trefis.com.
Investors holding Moderna (MRNA) face a choice between taking some of their gain and adding more shares. The stock has returned 1005.6% over the past year, compared with 13.7% for the S&P 500. That decision became harder on November 6, 2026, when Moderna reported a profit for the third quarter and raised its sales outlook for the year. Is that profit the start of a steadier business, or one strong vaccine season?
How Should You Read Moderna’s Third-Quarter Profit?
That quarterly profit must be read against the whole year. About 52% of Moderna’s sales over the twelve months to September 2026 arrived in that single quarter. The company’s sales rise and fall with the vaccine season, while its research and running costs accrue every quarter. A vaccine maker booking most of its sales in the autumn can post a profit for that period but still end the year in a loss, as expenses continue through quieter months. So you learn whether a business like this pays its way from its margin over four quarters, not from one season.
Moderna Made A Profit In One Of Four Quarters
Moderna generated $1.31 billion in revenue during the third quarter of 2026, up 30.9% from a year earlier. The company posted $0.13 billion in operating income, compared with an operating loss of $0.26 billion in the same quarter of 2025. Management said on the November 6 call that these stronger-than-expected sales came from a mix of higher demand, execution and the timing of shipments between the third and fourth quarters. This means a portion of the quarter’s strength reflects when doses shipped.
The other three quarters in those twelve months all ended in operating losses, the largest $1.39 billion in the first quarter of 2026. Over the twelve months, Moderna’s operating margin was -116.3%, a loss larger than its sales, while the S&P 500 earned an operating margin of 19.0%. That loss includes a $900 million litigation settlement charge, which Moderna counts in its 2026 cost of sales.
What Are You Paying For Moderna’s Sales Today?
At the November 9 close, Moderna stock traded at 42.8 times its twelve-month sales, compared with 3.1 times for the S&P 500. Because the company lost money over that period, a price-to-earnings ratio is not meaningful for Moderna. The sales multiple sits that high because the share price has run far ahead of sales, which grew 14.4% over the same twelve months.
Management now expects faster growth for 2026 than previously forecast. On November 6, the company raised its revenue outlook for the year to growth of 15% to 25%, from up to 10%, citing a strong start to the season and its view into the fourth quarter.
Many holders may also be betting on cancer. During a late-stage melanoma trial, patients given Moderna’s Intismeran with pembrolizumab showed a 42% lower risk of the cancer returning or of death than patients given pembrolizumab alone. Moderna and its partner Merck are working to file the vaccine for approval in 2026, and management said it hopes for approval in 2027. Yet the vaccine lacks both an approval and a price today, and management called any talk of its price premature.
Moderna is expected to report next in February 2027, and its revenue growth for 2026, against management’s raised outlook, is the number to watch. Growth within or above that range would show the strong start to the season held through the fourth quarter, as management expects. Growth below it would suggest the third quarter’s profit came from one strong vaccine season rather than a steadier business.
Not Sure Moderna Is Worth It At This Price?
You don’t have to bet on one stock to earn. The Trefis Income Solution owns 50 companies chosen to keep paying dividends, each with at least 10 straight years of dividends, yielding about 3x the S&P 500.
Spot an error or want more like this? Tell us in 10 seconds.